Quantcast
Last updated on April 16, 2014 at 7:25 EDT

Latest Isoniazid Stories

2014-01-23 11:29:46

A major trial aiming to cut the rate of tuberculosis (TB) among South Africa's gold miners did not reduce the number of cases or deaths from the disease, according to a study published in the New England Journal of Medicine. Researchers from the London School of Hygiene & Tropical Medicine say that the results demonstrate the scale of the TB problem in South African gold mines, and highlight the need for a "combination prevention" approach to improve TB control. The TB epidemic in...

2013-08-16 10:33:26

Study shows isoniazid therapy should be considered for millions of HIV-infected people globally As part of the largest international research effort ever made to combat tuberculosis, a team of Johns Hopkins and Brazilian experts has found that preventive antibiotic therapy for people with HIV lowers this group's chances of developing TB or dying. Specifically, they found in men and women already infected with HIV that taking isoniazid reduced deaths and new cases of active TB disease by 31...

2013-05-21 12:28:40

NEW YORK, May 21, 2013 /PRNewswire-USNewswire/ -- In a striking, unexpected discovery, researchers at Albert Einstein College of Medicine of Yeshiva University have determined that vitamin C kills drug-resistant tuberculosis (TB) bacteria in laboratory culture. The finding suggests that vitamin C added to existing TB drugs could shorten TB therapy, and it highlights a new area for drug design. The study was published today in the online journal Nature Communications. (Logo:...

2012-06-17 23:01:34

Immune Network Ltd. (IMMFF), announces the completion of a Phase II trial of a once-daily M. vaccae pill (V7) conducted by Immunitor in Ukraine. The imm02 study was aimed to seek whether oral formulation of inactivated whole cell mycobacteria can shorten TB treatment duration. Vancouver, Canada (PRWEB) June 17, 2012 The phase II, placebo-controlled trial, conducted by experts in the field of TB immunotherapy, was set to evaluate the efficacy of tableted, heat-killed Mycobacterium vaccae in...

2012-06-08 05:20:54

(Ivanhoe Newswire) -- In 2010 the World Health Organization (WHO) estimated there were 290,000 cases of multi-drug resistant tuberculosis globally. Now a new medication attempts to slash those numbers. Delamanid, a nitro-dihydro-imidazooxazole derivative, is a new medication that inhibits mycolic acid synthesis (long fatty acids found in the cell walls of the mycolata taxon) and has shown potent in vitro (half living-in a Petri dish) and in vivo (living in the body) activity against drug...

2012-03-27 08:34:42

A two-drug combination is one of the most promising advances in decades for the treatment of tuberculosis (TB) – a disease that kills 2 million people annually – a scientist reported today at the 243 National Meeting & Exposition of the American Chemical Society (ACS). The treatment, which combines two medications already approved by the U.S. Food and Drug Administration (FDA), delivers a knockout punch to forms of TB that shrug off other antibiotics. ACS, the world's...

2011-08-04 13:17:52

The European Respiratory Journal is today (04 August 2011) publishing the updated guidelines of the World Health Organization (WHO) that aim to help manage drug-resistant tuberculosis (TB). The new document 'The WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update' focuses on priority areas for healthcare professionals in the diagnosis, treatment and care of drug-resistant TB. It also calls for more research to guide the management of the condition. TB is...

2011-07-07 14:55:35

Johns Hopkins and South African scientists have further compelling evidence that new, simpler and shorter treatments with antibiotic drugs could dramatically help prevent tens of millions of people worldwide already infected with the bacterium responsible for tuberculosis, and especially those co-infected with HIV, from developing full-blown TB. That population includes as many as 22 million in sub-Saharan Africa who are already HIV positive and at high risk of also picking up TB, which is...

2011-04-13 07:43:06

(Ivanhoe Newswire) -- In patients with newly-diagnosed tuberculosis (TB), use of a combined four-drug, fixed-dose regimen was found to have comparable outcomes to drugs administered separately, according to a new study. "Despite the availability of a highly effective 6-month chemotherapy regimen, worldwide control of tuberculosis is severely impeded by poor treatment completion rates that threaten the emergence of multidrug resistance," according to background information in the article....

2011-03-16 13:57:21

The standard retreatment regimen for tuberculosis has low treatment response rates and is associated with poor long term outcomes in certain subgroups of patients, particularly those infected with both HIV and multi-drug resistant TB. These findings from a study by Edward Jones-L³pez from Boston University Medical School, Boston, USA, and colleagues and published in this week's PLoS Medicine, indicate that the standard retreatment approach to TB as implemented in low and middle-income...


Latest Isoniazid Reference Libraries

72_0ab04c9452ae9b3c6ae51f6deb1bcc35
2011-04-25 16:19:14

Mycobacterium tuberculosis (MTB) is a pathogenic bacterial species in the genus Mycobacterium and the causative agent of most cases of tuberculosis. Robert Koch first discovered it in 1882 and that it had an unusual, waxy coating on the cell surface which makes them impossible to Gram stain. M. tuberculosis is highly aerobic and requires high levels of oxygen. It generally infects the respiratory system of mammals. Tuberculin skin test, acid-fast stain, and chest radiographs are the most...

More Articles (1 articles) »